Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 3Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms by Site 2Lymphoma, Large-Cell, Anaplastic 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Salivary Gland Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms by Histologic Type 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma 1Intestinal Neoplasms 1Intestinal Diseases 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1

Interventions

pembrolizumab 3Trastuzumab 2Nivolumab 2tucatinib 1regorafenib 1pertuzumab 1niraparib 1milademetan 1dostarlimab 1cobimetinib 1brigimadlin 1atezolizumab 1alectinib 1Vemurafenib 1Tomography, X-Ray Computed 1Ramucirumab 1Radiation 1Positron-Emission Tomography 1Paclitaxel 1Magnetic Resonance Imaging 1HhAntag691 1Fulvestrant 1Erlotinib Hydrochloride 1Clinical Trials, Phase II as Topic 1Carboplatin 1Brachytherapy 1Antibodies 1AZD9833 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × alectinib × Genitourinary × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡